Barco Demetra and Gnosco Dermicus merge into new digital health skin solutions company

Kortrijk, Belgium, 7 September 2022 - Barco’s Demetra business, a next-generation skin imaging solution, and Gnosco’s Dermicus business, a leading European teledermatology platform, have joined forces to help clinicians transform the diagnostic and treatment processes of skin conditions, when and where the patient needs it. The company, named Dermicus, will deliver teledermatology, telewoundcare and digital dermoscopy solutions.

Dermicus company logo

A seamless, unique fit 

Together, the Dermicus platform and the Demetra skin imaging solution will provide a unique end-to-end offering for both specialist clinicians and collaborative networks of primary care professionals, dermatologists and wound care specialists. The Gnosco and Demetra teams will combine into a single entity, majority-owned by Barco.    

“The synergy between our cultures, mission, and solutions will bring tremendous value to our clients. Gnosco has the experience of leading teledermatology implementations at scale in Sweden and the UK, while Demetra has built a strong client base in dermatology. Together we can accelerate our vision of helping our clients transform the way they diagnose and manage skin conditions,” says Dermicus CEO Peter Kinhan.

A dermatologist using the Demetra Scope to view a lesion on a patient's cheek

Leveraging entrepreneurship and expertise

Both Gnosco and Barco’s Healthcare division were built in close collaboration with leading healthcare providers. This will continue in the future. The focus on entrepreneurship will be maintained by setting Dermicus up as a separate entity, which is majority-owned by Barco, to ensure the global resources and expertise of Barco can continue to be leveraged. Gnosco’s co-founders, Daniel Eliasson and Dr Johan Heilborn, will take on leadership roles as COO and CMO respectively.  

“This represents an important next step for Dermicus after years of investment and learning from leading some of Europe’s larger teledermatology implementations. As a combined team we can now expand to new regions and deepen our capabilities in telewoundcare and artificial intelligence, and continue to build on our new vision for digital dermoscopy,” says Daniel Eliasson, Dermicus COO.

 

About Barco 

Barco is a global technology leader that develops networked visualization solutions for the entertainment, enterprise and healthcare markets. Our solutions make a visible impact, allowing people to enjoy compelling entertainment experiences; to foster knowledge sharing and smart decision-making in organizations and to help hospitals provide their patients with the best possible healthcare.

Headquartered in Kortrijk (Belgium), Barco realized sales of 804 million euro in 2021 and has a global team of 3,000+ employees, whose passion for technology is captured in +500 granted patents. Barco has been listed on the Brussels Stock Exchange since 1985. (Euronext: BAR; Reuters: BARBt.BR; Bloomberg: BAR BB)

Get the latest market and trend insights in our brand magazine 'Bright Insights'. And visit us on www.barco.comTwitterLinkedInYouTube, Instagram, and Facebook.

About Gnosco

Gnosco is digital health company focused on solutions for skin cancer, general dermatology and hard-to-heal wounds.  Their platform Dermicus, CE certified as a medical device, was developed to support collaboration between primary care and specialists to be better diagnose and treat skin conditions.  Gnosco has been a pioneer in teledermatology in Sweden and the UK and has also expanded into the telewoundcare market.  On top of their innovative technology, Gnosco has created custom clinical education and telemedicine best practices to guide their clients through the change process to enable strong primary care collaboration with Dermatologists and wound care specialists.

Copyright 2022 by Barco

For more information, please contact

Inge Govaerts picture 1 Inge Govaerts
Corporate Communications Officer
Barco nv

Telephone +32 56 36 80 52
inge.govaerts@barco.com

Subscribe to press alerts